Immunomedicine
Biotechnology company developing platform-based immunotherapeutic drugs for cancer and drug‑resistant infectious diseases. Uses a viral‑derived vector delivery system to activate intracellular innate immunity (RIG-I) and combines gene, nucleic acid and cell therapy approaches. Operates university‑affiliated laboratory facilities and pursues academic and industry collaborations, pre‑IND regulatory engagement, and global commercialization planning.
Industries
Nr. of Employees
small (1-50)
Immunomedicine
Head Office: 4-1-3 Bingocho, Chuo-ku, Osaka 541-0051, Japan (Midosuji Mitsui Building, 4th floor, Lifescience HUB West)
Patents
Methods for the production of hemagglutinating virus of Japan and adenovirus using cultured cells
US-8012749-B2
View Details
Methods for the production of hemagglutinating virus of Japan and adenovirus using cultured cells
US-8012749-B2
View DetailsProducts
Vector-based nucleic acid delivery platform
A viral‑derived vector delivery platform designed to carry nucleic acid payloads and activate intracellular innate immune pathways to enhance cellular immunity for therapeutic applications.
Plasmid DNA therapeutic constructs
Plasmid DNA constructs under development, including examples encoding human CXCL2 and antigen + immune activator combinations (e.g., HSP65 + IL‑12), intended to recruit immune cells and activate cellular immunity.
Vector-based nucleic acid delivery platform
A viral‑derived vector delivery platform designed to carry nucleic acid payloads and activate intracellular innate immune pathways to enhance cellular immunity for therapeutic applications.
Plasmid DNA therapeutic constructs
Plasmid DNA constructs under development, including examples encoding human CXCL2 and antigen + immune activator combinations (e.g., HSP65 + IL‑12), intended to recruit immune cells and activate cellular immunity.
Services
Joint research partnerships with academic and industry organizations to co‑develop immunotherapeutic candidates and share R&D resources.
Joint research partnerships with academic and industry organizations to co‑develop immunotherapeutic candidates and share R&D resources.
Expertise Areas
- Immunotherapy platform development
- Nucleic acid therapeutics (mRNA, siRNA, plasmid DNA)
- Vector-mediated drug delivery
- Immuno-oncology preclinical research
Key Technologies
- Vector-mediated nucleic acid delivery
- Plasmid DNA engineering
- mRNA and siRNA therapeutics
- Innate immune receptor (RIG-I) activation
News & Updates
Announcement of the launch of the company's English website on November 8, 2024.
Won the Grand Prize and sponsor awards at The JSSA KANSAI Pitch Award hosted by the Japan Startup Support Association.
Secured funding through a J‑KISS financing instrument.
Won the Grand Prize at The JSSA Tokyo Pitch Award & Power Matching Booth Vol.58 hosted by the Japan Startup Support Association.
Announcement of the launch of the company's English website on November 8, 2024.
Won the Grand Prize and sponsor awards at The JSSA KANSAI Pitch Award hosted by the Japan Startup Support Association.
Secured funding through a J‑KISS financing instrument.
Won the Grand Prize at The JSSA Tokyo Pitch Award & Power Matching Booth Vol.58 hosted by the Japan Startup Support Association.